https://www.maximizemarketresearch.com/market-report/intravenous-solution-market/73970/

Intraocular lens market is projected to grow significantly over the forecast period. It is estimated that the market is expected to register a CAGR of 5.17% during the forecast period of 2020–2030 with an estimated market value of 5,067.05 billion in 2030.

The global Intravenous (IV) solutions market size USD 7.8 Billion in 2022 and is expected to reach USD 12.5 Billion by 2032, and register a rapid revenue CAGR of 4.8% during the forecast period.

Intravenous Solutions Market: Advancements and Opportunities

A) Market Overview: The global Intravenous Solutions Market is estimated to be valued at US$ 9,907.8 million  in 2022 and is expected to exhibit a CAGR of 6.1%  over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Intravenous solutions, also known as IV fluids, are used to deliver vital nutrients, medications, and fluids directly into the veins. This method allows for rapid absorption and distribution throughout the body. IV solutions play a crucial role in emergency care, surgical procedures, and the treatment of various medical conditions. The need for intravenous solutions arises in situations where oral intake of fluids or medications is not possible, such as in patients with severe dehydration, electrolyte imbalances, or those who are unable to swallow. The advantages of IV solutions include immediate and efficient delivery of fluids, better control over dosages, and the ability to administer medications directly into the bloodstream for quick and targeted action. B) Market Key Trends: One key trend in the Intravenous Solutions Market Size is the increasing demand for specialty parenteral nutrition solutions. Parenteral nutrition refers to the provision of nutrients intravenously to patients who are unable to consume adequate oral or enteral nutrition. These solutions are customized according to the specific nutritional requirements of each patient. With the rising prevalence of chronic diseases and malnutrition, the demand for specialty parenteral nutrition solutions is expected to grow. For instance, Baxter International Inc. offers various parenteral nutrition solutions, including those for patients with specific conditions like renal impairment, liver disease, or metabolic disorders. These solutions are designed to provide optimal nutrition and support recovery in patients with complex medical needs. C) Porter's Analysis: - Threat of new entrants: The market has high barriers to entry due to the stringent regulatory requirements and the need for substantial investments in research and development. Established players with strong distribution networks have a competitive advantage. - Bargaining power of buyers: Buyers have moderate bargaining power due to the presence of several suppliers in the market. However, the criticality of IV solutions in healthcare settings gives suppliers some leverage. - Bargaining power of suppliers: Suppliers have moderate bargaining power due to the presence of multiple buyers in the market. However, the quality and reliability of IV solutions play a crucial role, giving buyers some influence. - Threat of new substitutes: There is a low threat of substitutes for IV solutions, as they are essential for efficient and targeted administration of fluids and medications. - Competitive rivalry: The market is highly competitive, with key players continuously investing in research and development and launching innovative solutions to gain a competitive edge. Baxter International Inc., ICU Medical Inc., and B. Braun Melsungen AG are among the key players dominating the market. D) Key Takeaways: - The global Intravenous Solutions Market is expected to witness high growth, exhibiting a CAGR of 6.1%  over the forecast period, due to increasing demand for specialty parenteral nutrition solutions and advancements in medical technology. - Regionally, North America is expected to dominate the market due to the presence of a well-established healthcare infrastructure and high adoption of advanced medical treatments. Asia-Pacific is anticipated to be the fastest-growing region, driven by increasing healthcare expenditure and a growing population. - Key players operating in the global Intravenous Solutions Market include Baxter International Inc., ICU Medical Inc., B. Braun Melsungen AG, Grifols S.A., and Fresenius Kabi USA, among others. These players focus on strategic collaborations, product launches, and geographic expansions to strengthen their market position.

Global Intravenous Solutions Market Is Estimated To Witness High Growth Owing To Growing Demand For Intravenous Therapy

A) Market Overview: Intravenous solutions are sterile fluids that are administered through veins to provide necessary fluids, electrolytes, medications, and nutrients directly into the bloodstream. These solutions are widely used in hospitals, clinics, and home-based settings to effectively deliver medications and treat various medical conditions. The advantages of intravenous solutions include immediate absorption, precise dosage calculation, and the ability to deliver a diverse range of medications.

The global Intravenous Solutions Market Size is estimated to be valued at US$ 9,907.8 million in 2022 and is expected to exhibit a CAGR of 6.1% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights. B) Market Key Trends: One key trend in the global intravenous solutions market is the increasing demand for intravenous therapy. The growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders has led to an increased need for intravenous treatments. Intravenous therapy provides a direct route for administering medications and fluids into the bloodstream, ensuring quick and effective absorption. This trend is further supported by advancements in technology and the development of innovative delivery systems that improve patient outcomes and enhance the overall healthcare experience. For example, the introduction of ambulatory infusion pumps has revolutionized intravenous therapy by allowing patients to receive treatment outside of medical facilities. These portable devices provide continuous administration of fluids and medications, enabling patients to maintain their daily activities while receiving necessary treatments. C) PEST Analysis: - Political: Government regulations and policies regarding the production, distribution, and quality control of intravenous solutions can impact market growth. - Economic: The economic stability of a region can influence market demand, as healthcare expenditure and affordability play a crucial role in the adoption of intravenous solutions. - Social: The increasing aging population, rising healthcare awareness, and the prevalence of chronic diseases drive the demand for intravenous solutions. - Technological: Advances in technology have led to the development of innovative intravenous delivery systems, such as smart pumps and needleless connectors, improving the safety and efficiency of intravenous therapy. D) Key Takeaways: The global intravenous solutions market is expected to witness high growth, exhibiting a CAGR of 6.1% over the forecast period. This growth is driven by increasing demand for intravenous therapy, as it provides a direct and effective route for medication administration. For example, patients with cancer or chronic diseases require intravenous treatments for optimal outcomes. In terms of regional analysis, North America is expected to dominate the global market due to well-established healthcare infrastructure and high adoption of advanced medical technologies. However, the Asia Pacific region is projected to be the fastest-growing market, driven by the increasing geriatric population, rising disposable income, and improving healthcare infrastructure in countries like China and India. Key players operating in the global Intravenous Solutions Market include Baxter International Inc., ICU Medical Inc., B. Braun Melsungen AG, Grifols S.A., Fresenius Kabi USA LLC, Vifor Pharma Management Ltd, JW Life Science, Amanta Healthcare, Axa Parenterals Ltd, Salius Pharma Private Limited, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd, Ajinomoto Co., Inc., B. Braun Melsungen AG, Soxa Formulations & Research Pvt. Ltd, and Sichuan Kelun Pharmaceutical Co Ltd. These companies focus on product development, strategic collaborations, and mergers and acquisitions to strengthen their market presence and expand their product portfolios. In conclusion, the global intravenous solutions market is expected to witness significant growth due to the increasing demand for intravenous therapy. Advancements in technology and innovative delivery systems further support this trend. However, factors such as government regulations and economic stability can impact market growth. North America is currently the dominant market, but the Asia Pacific region is expected to witness rapid growth. Key players in the market are investing in product development and strategic collaborations to maintain their competitive edge.

Intravenous Solutions Market Sales Revenue Strategies Insights 2022-2032 | Amanta Healthcare, Axa Parenterals Ltd., B. Braun Melsungen Ag

Intravenous Solutions Market Sales Revenue Strategies Insights 2022-2032 | Amanta Healthcare, Axa Parenterals Ltd., B. Braun Melsungen Ag

insightSLICE has compiled key insights and presented a research report on market titled “Global Intravenous Solutions Market 2023”: The report begins with an overview of the industrial environment, analysis of market size, by-products, regions, application, industry competition within active companies. The research analyzes market share, demand, trends and forecast in the coming years. The report…

View On WordPress

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Global Intravenous Solutions Market Trends, Share, Size, Growth, Opportunities, and Forecast to 2022-2030

The launch of new intravenous injection solutions by Intravenous Solutions Market participants is anticipated to spur the market's expansion over the forecast period. One such example is the commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection, which was approved by the U.S. Food and Drug Administration (FDA) and announced by Baxter International Inc. in September 2021. (norepinephrine). Adult patients with severe, acute hypotension should take norepinephrine to raise their blood pressure (low blood pressure). Norepinephrine is available in Baxter's formulation in strengths of 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL), making it the first and only manufacturer-prepared ready-to-use formulation.

Read More @

https://cmiinfonest.blogspot.com/2022/08/intravenous-solutions-market-global.html

A recent report provides crucial insights along with application based and forecast information in the Global Intravenous Solutions (Colloids) Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Intravenous Solutions (Colloids) market.

Horseshoe crab blood is vital for testing intravenous drugs, but new synthetic alternatives could mean pharma won’t bleed this unique species dry

- By Kristoffer Whitney , Jolie Crunelle , Rochester Institute of Technology , The Conversation -

If you have ever gotten a vaccine or received an intravenous drug and did not come down with a potentially life-threatening fever, you can thank a horseshoe crab (Limulus polyphemus).

How can animals that are often called living fossils, because they have barely changed over millions of years, be so important in modern medicine? Horseshoe crab blood is used to produce a substance called limulus amebocyte lysate, or LAL, which scientists use to test for toxic substances called endotoxins in intravenous drugs.

These toxins, produced by bacteria, are ubiquitous in the environment and can’t be removed simply through sterilization. They can cause a reaction historically referred to as “injection fever.” A strong concentration can lead to shock and even death.

Identifying LAL as a highly sensitive detector of endotoxins was a 20th-century medical safety breakthrough. Now, however, critics are raising questions about environmental impacts and the process for reviewing and approving synthetic alternatives to horseshoe crab blood.

We study science, technology and public policy, and recently published a white paper examining social, political and economic issues associated with using horseshoe crabs to produce LAL. We see this issue as a test case for complicated problems that cut across multiple agencies and require attention to both nature and human health.

Protecting horseshoe crabs will require persuading the heavily regulated pharmaceutical industry to embrace change.

An ocean solution

Doctors began injecting patients with various solutions in the mid-1800s, but it was not until the 1920s that biochemist Florence Seibert discovered that febrile reactions were due to contaminated water in these solutions. She created a method for detecting and removing the substances that caused this reaction, and it became the medical standard in the 1940s.

Known as the rabbit pyrogen test, it required scientists to inject intravenous drugs into rabbits, then monitor the animals. A feverish rabbit meant that a batch of drugs was contaminated.

The LAL method was discovered by accident. Working with horseshoe crabs at the Marine Biological Laboratory at Woods Hole, Massachusetts, in the 1950s and ’60s, pathobiologist Frederik Bang and medical researcher Jack Levin noticed that the animals’ blue blood coagulated in a curious manner. Through a series of experiments, they isolated endotoxin as the coagulant and devised a method for extracting LAL from the blood. This compound would gel or clot nearly instantaneously in the presence of fever-inducing toxins.

Academic researchers, biomedical companies and the U.S. Food and Drug Administration refined LAL production and measured it against the rabbit test. By the 1990s, LAL was the FDA-approved method for testing medicines for endotoxin, largely replacing rabbits.

Producing LAL requires harvesting horseshoe crabs from oceans and beaches, draining up to 30% of their blood in a laboratory and returning the live crabs to the ocean. There’s dispute about how many crabs die in the process – estimates range from a few percent to 30% or more – and about possible harmful effects on survivors.

Today there are five FDA-licensed LAL producers along the U.S. East Coast. The amount of LAL they produce, and its sales value, are proprietary.

Bait versus biotech

As biomedical LAL production ramped up in the 1990s, so did harvesting horseshoe crabs to use as bait for other species, particularly eel and whelk for foreign seafood markets. Over the past 25 years, hundreds of thousands – and in the early years, millions – of horseshoe crabs have been harvested each year for these purposes. Combined, the two fisheries kill over half a million horseshoe crabs every year.

There’s no agreed total population estimate for Limulus, but the most recent federal assessment of horseshoe crab fisheries found the population was neither strongly growing nor declining.

Conservationists are worried, and not just about the crabs. Millions of shorebirds migrate along the Atlantic coast, and many stop in spring, when horseshoe crabs spawn on mid-Atlantic beaches, to feed on the crabs’ eggs. Particularly for red knots – a species that can migrate up to 9,000 miles between the tip of South America and the Canadian Arctic – gorging on horseshoe crab eggs provides a critical energy-rich boost on their grueling journey.

Red knots were listed as threatened under the Endangered Species Act in 2015, largely because horseshoe crab fishing threatened this key food source. As biomedical crab harvests came to equal or surpass bait harvests, conservation groups began calling on the LAL industry to find new sources.

Biomedical alternatives

Many important medicines are derived from living organisms. Penicillin, the first important antibiotic, was originally produced from molds. Other medicines currently in use come from sources including cows, pigs, chickens and fish. The ocean is a promising source for such products.

When possible, synthesizing these substances in laboratories – especially widely used medications like insulin – offers many benefits. It’s typically cheaper and more efficient, and it avoids putting species at risk, as well as addressing concerns some patients have about using animal-derived medical products.

In the 1990s, researchers at the National University of Singapore invented and patented the first process for creating a synthetic, endotoxin-detecting compound using horseshoe crab DNA and recombinant DNA technology. The result, dubbed recombinant Factor C (rFC), mimicked the first step in the three-part cascade reaction that occurs when LAL is exposed to endotoxin.

Later, several biomedical firms produced their own versions of rFC and compounds called recombinant cascade reagents (rCRs), which reproduce the entire LAL reaction without using horseshoe crab blood. Yet, today, LAL remains the dominant technology for detecting endotoxins in medicine.

A sample of horseshoe crab blood. Florida Fish and Wildlife Commission, CC BY-NC-ND

The main reason is that the U.S. Pharmacopeia, a quasi-regulatory organization that sets safety standards for medical products, considers rFC and rCR as “alternative” methods for detecting endotoxins, so they require case-by-case validation for use – a potentially lengthy and expensive process. The FDA generally defers to the U.S. Pharmacopeia.

A few large pharmaceutical companies with deep pockets have committed to switching from LAL to rFC. But most drug producers are sticking with the tried-and-true method.

Conservation groups want the U.S. Pharmacopeia to fully certify rFC for use in industry with no extra testing or validation. In their view, LAL producers are stalling rFC and rCR approval to protect their market in endotoxin detection. The U.S. Pharmacopeia and LAL producers counter that they are doing due diligence to protect public health.

Change in the offing

Change may be coming. All major LAL producers now have their own recombinant products – a tacit acknowledgment that markets and regulations are moving toward Limulus-free ways to test for endotoxins.

Atlantic fisheries regulators are currently considering new harvest limits for horseshoe crabs, and the U.S. Pharmacopeia is weighing guidance on recombinant alternatives to LAL. Public comments will be solicited over the winter of 2024, followed by U.S. Pharmacopeia and FDA review.

Even if rFC and rCR don’t win immediate approval, we believe that collecting more complete data on horseshoe crab populations and requiring more transparency from the LAL industry on how it handles the crabs would represent progress. So would directing medical companies to use recombinant products for testing during the manufacturing process, while saving LAL solely for final product testing.

Making policy on complex scientific issues across diverse agencies is never easy. But in our view, incremental actions that protect both human health and the environment could be important steps forward.

Kristoffer Whitney, Associate Professor of Science, Technology and Society, Rochester Institute of Technology and Jolie Crunelle, Master's Degree Student in Science, Technology, and Public Policy, Rochester Institute of Technology

This article is republished from The Conversation under a Creative Commons license. Read the original article.

--

Read Also

The FDA no longer mandates all drugs to be tested on animals before being tested on humans